Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

Science

Volumn 285, Issue 5428, 1999, Pages 732-736

  Brightbill, Hans D ^a   Libraty, Daniel H ^a   Krutzik, Stephan R ^a   Yang, Ruey Bing ^b   Belisle, John T ^c   Bleharski, Joshua R ^a   Maitland, Michael ^d   Norgard, Michael V ^e   Plevy, Scott E ^f   Smale, Stephen T ^a   Brennan, Patrick J ^c   Bloom, Barry R ^d,g   Godowski, Paul J ^b   Modlin, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; LIPOPROTEIN; MEMBRANE RECEPTOR; NITRIC OXIDE SYNTHASE;

ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; GENE ACTIVATION; HOST RESISTANCE; HUMAN; HUMAN CELL; INFECTION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, BACTERIAL; CELL LINE; DROSOPHILA PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LIPOPROTEINS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0033618562     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5428.732     Document Type: Article

References (64)

1. J. Maillard and B. R. Bloom, J. Exp. Med. 136, 185 (1972).
2. M. Zhang et al., J. Clin. Invest. 93, 1733 (1994).
3. T. M. Scharton and P. Scott, J. Exp. Med. 178, 567 (1993).
4. F. P. Heinzet, D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, M. K. Gately, ibid. 177, 1505 (1993); J. P. Sypek et al., ibid., p. 1797; L. C. C. Afonso et al., Science 263, 235 (1994).
5. F. P. Heinzet, D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, M. K. Gately, ibid. 177, 1505 (1993); J. P. Sypek et al., ibid., p. 1797; L. C. C. Afonso et al., Science 263, 235 (1994).
6. F. P. Heinzet, D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, M. K. Gately, ibid. 177, 1505 (1993); J. P. Sypek et al., ibid., p. 1797; L. C. C. Afonso et al., Science 263, 235 (1994).
7. J. L. Flynn et al., J. Immunol. 155, 2515 (1995); A. M. Cooper et al., Immunology 84, 423 (1995).
8. J. L. Flynn et al., J. Immunol. 155, 2515 (1995); A. M. Cooper et al., Immunology 84, 423 (1995).
9. F. Altare et al., Science 280, 1432 (1998); R. de Jong et al., ibid., p. 1435.
10. F. Altare et al., Science 280, 1432 (1998); R. de Jong et al., ibid., p. 1435.
11. K. M. Dobos, K. Swiderek, K. H. Khoo, P. J. Brennan, J. T. Belisle, Infect. Immun. 63, 2846 (1995).
12. 2 incubator with RPMI 1640 and 10% heat-inactivated fetal bovine serum (FBS). Cell-free supernatants were harvested 20 hours later and stored at -20°C until assayed for cytokine concentrations by ELISA as previously described (38, 39). The amount of lipopolysaccharide in all preparations was measured quantitatively with a Limulus Amoebocyte Lysate assay (Whittaker Bioproducts, Walkersville, MD) and found to be <40 pg per microgram of M. tuberculosis fraction or protein, an amount that did not stimulate IL-12 activity by itself.
13. The mycolyl arabinogalactan peptidoglycan complex (mAGP) was also derived from the cell wall pellet after SDS detergent extraction. Most of the IL-12 p40-inducing activity was associated with the SCWP fraction compared with mACP (see supplementary material available at www.sciencemag.org/feature/ data/1040444.shl). Because macrophage phagocytosis of protein-adsorbed particulate suspensions has been reported to induce IL-12 release, we filtered both fractions through a 0.2-μm sterile filter. The SCWP fraction retained most of its IL-12 p40-inducing activity after filtration, whereas the mAGP suspension did not induce IL-12 p40.
14. 3. At each step, fractions were tested for their ability to induce IL-12 p40, and the fractions with potent activity were further purified. Rotofor fraction number 4 was electrophoresed under denaturing conditions on a 4 to 20% trisglycine minigel and transferred to nitrocellulose. Areas containing the four protein bands noted in Fig. 1B were isolated and solubilized as described previously (11) and used to stimulate THP-1 cells.
15. R. S. Wallis, M. Amir Tahmasseb, J. J. Ellner, Proc. Natl. Acad. Sci. U.S.A. 87, 3348 (1990).
16. K. R. Ashbridge, R. J. Booth, J. D. Watson, R. B. Lathigra, Nucleic Acids Res. 17, 1249 (1989); D. B. Young and T. R. Garbe, Res. Microbiol. 142, 55 (1991).
17. K. R. Ashbridge, R. J. Booth, J. D. Watson, R. B. Lathigra, Nucleic Acids Res. 17, 1249 (1989); D. B. Young and T. R. Garbe, Res. Microbiol. 142, 55 (1991).
18. 2 incubator with RPMI 1640 and 10% heat-inactivated FBS. Nonadherent cells were removed and the medium replaced with the addition of 19-kD lipoprotein at 1, 10, and 100 ng/ml. Neutralizing monoclonal antibody to human TNF-α (Endogen, Cambridge, MA; Biosource, Camarillo, CA) and a mouse isotype control [immunoglobulin G1 (IgG1)] were added to some cultures at 5 and 10 μg/ml. Supematants were harvested 16 hours later and assayed by IL-12 p40 ELISA (Pharmingen, San Diego, CA). All samples were assayed in duplicate. Previously, it was demonstrated that mycobacteria infection does not induce IL-12 in TNFR1 knockout animals [I. E. Flesch et al., J. Exp. Med. 181, 1615 (1995)].
19. Adherent monocytes were isolated from 11 tuberculin-negative healthy donors (13). Cells were stimulated with the 19-kD lipoprotein at a concentration of 10 ng/ml for 20 hours, and IL-12 p70 amounts were determined by ELISA with monoclonal anti-IL-12 p70 and antibodies 2OC2 and POD-4D6 as described (39). Under these conditions the monocytes from 8 out of 11 donors were able to produce measurable IL-12 p70 amounts 3 to 13 times above background levels in the range of 10 to 40 pg/ml. All samples were assayed in duplicate.
20. S. E. Plevy, J. H. Gemberting, S. Hsu, A. J. Dorner, S. T. Smale, Mol. Cell Biol. 17, 4572 (1997).
21. All RAW 264.7 cell (ATCC, Manassas, VA) transfections were carried out with the Superfect protocol (Qiagen, Valencia, CA) at a ratio of 1 μg of DNA to 3 μl of Superfect for 2.5 hours. After a PBS wash, cells were divided into two wells and left unactivated or stimulated with LPS or lipoproteins for 24 hours and then harvested for the chloramphenicol acetyltransferase (CAT) assay. In IL-12 p40 and inducible nitric oxide synthase [iNOS) promoter induction studies, RAW 264.7 cells were transiently transfected with either IL-12 p40 (15) or iNOS promoter (36), CAT reporter plasmid (2 μg), and HSP70-β-Gal construct (0.5 μg) as an internal control In the TLR-2 dn1 overexpression experiments, increasing doses of TLR-2 dn1 expression plasmid (100 ng, 500 ng, 1 μg, and 2 μg) (19) were transfected with the IL-12 p40 promoter construct and β-Gal as an internal control. The amount of expression plasmid was normalized to 2 μg with expression plasmid lacking the TLR-2 dn1 coding sequence (pCDNA3). IL-12 p40 promoter transfectants were either left unactivated or stimulated with LPS, 19-kD lipoprotein, or OspA at 50 ng/ml or Tp47 lipopeptide (24) at 10 μM for 24 hours. iNOS promoter transfectants were stimulated with LPS, 19-kD lipoprotein, OspA, or deacylated OspA (d-OspA) from 0.01 to 100 ng/ml, or left unstimulated for 24 hours. The iNOS promoter was also cotransfected with the TLR-2 dn1 construct (1 μg) or vector control (1 μg) and stimulated with LPS at 1 ng/ml, 19-kD lipoprotein and OspA at 5 ng/ml, or Tp47 lipopeptide at 10 μM for 24 hours. IL-12 p40 and iNOS promoter activities were measured according to CAT activity (percent chloramphenicol acetylation) with a phosphorimager. Data were normalized to a cotransfected β-Gal construct for transfection efficiency.
22. X. Ma et al., J. Exp. Med. 183, 147 (1996); T. L. Murphy, M. G. Cleveland, P. Kulesza, J. Magram, K. M. Murphy, Mol. Cell Biol. 15, 5258 (1995).
23. X. Ma et al., J. Exp. Med. 183, 147 (1996); T. L. Murphy, M. G. Cleveland, P. Kulesza, J. Magram, K. M. Murphy, Mol. Cell Biol. 15, 5258 (1995).
24. R. Medzhitov, P. Preston-Hurlburt, C. A. J. Janeway, Nature 388, 394 (1997).
25. R. B. Yang et al., ibid. 395, 284 (1998).
26. M. Muzio, G. Natoli, S. Saccani, M. Levrero, A. Mantovani, J. Exp. Med. 187, 2097 (1998); C. J. Kirschning, H. Wesche, T. M. Ayres, M. Rothe, ibid. 188, 2091 (1999).
27. M. Muzio, G. Natoli, S. Saccani, M. Levrero, A. Mantovani, J. Exp. Med. 187, 2097 (1998); C. J. Kirschning, H. Wesche, T. M. Ayres, M. Rothe, ibid. 188, 2091 (1999).
28. An IL-1R expression construct was cotransfected with the IL-12 p40 promoter in a titration of plasmid (0.1, 0.5. 1, and 2 μg) as was done with the TLR-2 dn1 mutant construct (16). Overexpression of IL-1R had no effect on IL-12 p40 promoter activation by LPS or lipoproteins even at the highest levels of expression, suggesting that mere overexpression of a related surface receptor does not have an effect on IL-12 p40 promoter activation.
29. V. Braun and K. Hantke, Annu. Rev. Biochem. 43, 89 (1974); J. D. Radolf, N. R. Chamberlain, A. Clausell, M. V. Norgard, Infect. Immun. 56, 490 (1988); N. R. Chamberlain, M. E. Brandt, A. L Erwin, J. D. Radolf, M. V. Norgard, ibid. 57, 2872 (1989); T. M. Bricker, M. J. Boyer, J. Keith, R. Watson-McKown, K. S. Wise, ibid. 56, 295 (1988).
30. V. Braun and K. Hantke, Annu. Rev. Biochem. 43, 89 (1974); J. D. Radolf, N. R. Chamberlain, A. Clausell, M. V. Norgard, Infect. Immun. 56, 490 (1988); N. R. Chamberlain, M. E. Brandt, A. L Erwin, J. D. Radolf, M. V. Norgard, ibid. 57, 2872 (1989); T. M. Bricker, M. J. Boyer, J. Keith, R. Watson-McKown, K. S. Wise, ibid. 56, 295 (1988).
31. V. Braun and K. Hantke, Annu. Rev. Biochem. 43, 89 (1974); J. D. Radolf, N. R. Chamberlain, A. Clausell, M. V. Norgard, Infect. Immun. 56, 490 (1988); N. R. Chamberlain, M. E. Brandt, A. L Erwin, J. D. Radolf, M. V. Norgard, ibid. 57, 2872 (1989); T. M. Bricker, M. J. Boyer, J. Keith, R. Watson-McKown, K. S. Wise, ibid. 56, 295 (1988).
32. V. Braun and K. Hantke, Annu. Rev. Biochem. 43, 89 (1974); J. D. Radolf, N. R. Chamberlain, A. Clausell, M. V. Norgard, Infect. Immun. 56, 490 (1988); N. R. Chamberlain, M. E. Brandt, A. L Erwin, J. D. Radolf, M. V. Norgard, ibid. 57, 2872 (1989); T. M. Bricker, M. J. Boyer, J. Keith, R. Watson-McKown, K. S. Wise, ibid. 56, 295 (1988).
33. J. J. Weis, Y. Ma, L. F. Erdile, Infect. Immun. 62, 4632 (1994).
34. J. D. Radolf et al., J. Immunol. 154, 2866 (1995).
35. F. Melchers, V. Braun, C. Galanos, J. Exp. Med. 142, 473 (1975).
36. L. Biesert, W. Scheuer, W. G. Bessler, Eur. J. Biochem. 162, 651 (1987); S. Hauschildt et al., Eur. J. Immunol. 20, 63 (1990); W. G. Bessler and B. P. Ottenbreit, Biochem. Biophys. Res. Commun. 76, 239 (1976); W. G. Bessler et al., J. Immunol. 135, 1900 (1985); P. Hoffmann et al., Immunobiology 177, 158 (1988).
37. L. Biesert, W. Scheuer, W. G. Bessler, Eur. J. Biochem. 162, 651 (1987); S. Hauschildt et al., Eur. J. Immunol. 20, 63 (1990); W. G. Bessler and B. P. Ottenbreit, Biochem. Biophys. Res. Commun. 76, 239 (1976); W. G. Bessler et al., J. Immunol. 135, 1900 (1985); P. Hoffmann et al., Immunobiology 177, 158 (1988).
38. L. Biesert, W. Scheuer, W. G. Bessler, Eur. J. Biochem. 162, 651 (1987); S. Hauschildt et al., Eur. J. Immunol. 20, 63 (1990); W. G. Bessler and B. P. Ottenbreit, Biochem. Biophys. Res. Commun. 76, 239 (1976); W. G. Bessler et al., J. Immunol. 135, 1900 (1985); P. Hoffmann et al., Immunobiology 177, 158 (1988).
39. L. Biesert, W. Scheuer, W. G. Bessler, Eur. J. Biochem. 162, 651 (1987); S. Hauschildt et al., Eur. J. Immunol. 20, 63 (1990); W. G. Bessler and B. P. Ottenbreit, Biochem. Biophys. Res. Commun. 76, 239 (1976); W. G. Bessler et al., J. Immunol. 135, 1900 (1985); P. Hoffmann et al., Immunobiology 177, 158 (1988).
40. L. Biesert, W. Scheuer, W. G. Bessler, Eur. J. Biochem. 162, 651 (1987); S. Hauschildt et al., Eur. J. Immunol. 20, 63 (1990); W. G. Bessler and B. P. Ottenbreit, Biochem. Biophys. Res. Commun. 76, 239 (1976); W. G. Bessler et al., J. Immunol. 135, 1900 (1985); P. Hoffmann et al., Immunobiology 177, 158 (1988).
41. Y. Ma et al., Infect. Immun. 62, 3663 (1994).
42. A. O. Atiprantis et al., Science 285, 736 (1999).
43. THP-1 cells were stimulated with LPS, OspA, or d-OspA at 1 μg/ml (31). Supernatants were then assayed for IL-12 p40 by ELISA. LPS and OspA induced IL-12 p40 from THP-1 cells in a range of 1000 to 3500 pg/ml, whereas the amount of IL-12 p40 induced by d-OspA was below the level of detection.
44. 5 cells/well in six-well plates and transiently transfected them the following day with the NF-κB responsive E-selectin (ELAM) gene enhancer luciferase (pGL3) reporter gene (0.5 μg) and a β-galactosidase reporter plasmid (0.5 μg) as an internal control by the Superfect protocol at a 1:3 ratio of DNA (micrograms to Superfect (microliters). Cells were then incubated with the DNA-Superfect mixture for 2 hours and washed, and multiple transfectants were pooled and divided into separate wells for activation by a titration of LPS or lipoprotein stimuli (19-kD lipoprotein. Tp47, and OspA). Twenty-four hours later cells were stimulated for 6 hours then lysed in 200 μl of reporter lysis buffer (Promega, Madison, Wl), and 20 μl was used in the luciferase assay. HEK 293 control cells and TLR-2 stable clones were also cotransfected with a CD14 expression plasmid (19) (1 μg) or vector control (pCDNA3, 1 μg) with the same protocol.
45. T. J. Sellati et al., J. Immunol. 160, 5455 (1998); M. V. Norgard, B. S. Riley, J. A. Richardson, J. D. Radolf, Infect. Immun. 63, 1507 (1995); M. V. Norgard et al., ibid. 64, 3845 (1996).
46. T. J. Sellati et al., J. Immunol. 160, 5455 (1998); M. V. Norgard, B. S. Riley, J. A. Richardson, J. D. Radolf, Infect. Immun. 63, 1507 (1995); M. V. Norgard et al., ibid. 64, 3845 (1996).
47. T. J. Sellati et al., J. Immunol. 160, 5455 (1998); M. V. Norgard, B. S. Riley, J. A. Richardson, J. D. Radolf, Infect. Immun. 63, 1507 (1995); M. V. Norgard et al., ibid. 64, 3845 (1996).
48. R. M. Wooten et al., J. Immunol. 160, 5485 (1998).
49. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, F. Gusovsky, J. Biol. Chem. 274, 10689 (1999); K. Hoshino et al., J. Immunol. 162, 3749 (1999); S. T. Qureshi et al., J. Exp. Med. 189, 615 (1999); S. N. Vogel et al., J. Immunol. 162, 5666 (1999); R. Shimazu et al., J. Exp. Med. 189, 1777 (1999); A. Poltorak et al., Science 282, 2085 (1998).
50. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, F. Gusovsky, J. Biol. Chem. 274, 10689 (1999); K. Hoshino et al., J. Immunol. 162, 3749 (1999); S. T. Qureshi et al., J. Exp. Med. 189, 615 (1999); S. N. Vogel et al., J. Immunol. 162, 5666 (1999); R. Shimazu et al., J. Exp. Med. 189, 1777 (1999); A. Poltorak et al., Science 282, 2085 (1998).
51. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, F. Gusovsky, J. Biol. Chem. 274, 10689 (1999); K. Hoshino et al., J. Immunol. 162, 3749 (1999); S. T. Qureshi et al., J. Exp. Med. 189, 615 (1999); S. N. Vogel et al., J. Immunol. 162, 5666 (1999); R. Shimazu et al., J. Exp. Med. 189, 1777 (1999); A. Poltorak et al., Science 282, 2085 (1998).
52. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, F. Gusovsky, J. Biol. Chem. 274, 10689 (1999); K. Hoshino et al., J. Immunol. 162, 3749 (1999); S. T. Qureshi et al., J. Exp. Med. 189, 615 (1999); S. N. Vogel et al., J. Immunol. 162, 5666 (1999); R. Shimazu et al., J. Exp. Med. 189, 1777 (1999); A. Poltorak et al., Science 282, 2085 (1998).
53. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, F. Gusovsky, J. Biol. Chem. 274, 10689 (1999); K. Hoshino et al., J. Immunol. 162, 3749 (1999); S. T. Qureshi et al., J. Exp. Med. 189, 615 (1999); S. N. Vogel et al., J. Immunol. 162, 5666 (1999); R. Shimazu et al., J. Exp. Med. 189, 1777 (1999); A. Poltorak et al., Science 282, 2085 (1998).
54. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, F. Gusovsky, J. Biol. Chem. 274, 10689 (1999); K. Hoshino et al., J. Immunol. 162, 3749 (1999); S. T. Qureshi et al., J. Exp. Med. 189, 615 (1999); S. N. Vogel et al., J. Immunol. 162, 5666 (1999); R. Shimazu et al., J. Exp. Med. 189, 1777 (1999); A. Poltorak et al., Science 282, 2085 (1998).
55. J. Chan, Y. Xing, R. S. Magliozzo, B. R. Bloom, J. Exp. Med. 175, 1111 (1992); J. Chan, K. Tanaka, D. Carroll, J. Flynn, B. R. Bloom, Infect. Immun. 63, 736 (1995).
56. J. Chan, Y. Xing, R. S. Magliozzo, B. R. Bloom, J. Exp. Med. 175, 1111 (1992); J. Chan, K. Tanaka, D. Carroll, J. Flynn, B. R. Bloom, Infect. Immun. 63, 736 (1995).
57. J. D. MacMicking et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5243 (1997).
58. Q. W. Xie, R. Whisnant, C. Nathan, J. Exp. Med. 177, 1779 (1993).
59. 2 (Sigma) (40).
60. P. A. Sieling et al., J. Immunol. 153, 3639 (1994).
61. D. H. Libraty et al., J. Clin. Invest. 99, 336 (1997).
62. L. C. Green et al., Anal. Biochem. 126, 131 (1982).
63. Adherent monocytes were isolated as described previously (14). Cells were treated with no antibody, mouse anti-human TLR-2 neutralizing monoclonal antibody, or an isotype control mouse IgG1 (10 μg/ml) for 30 min before stimulation with LPS or 19-kD lipoprotein (50 ng/ml) and incubated for 16 hours. Supernatants were then harvested and assayed for IL-12 p40 by ELISA. CD40L- and interferon-γ (IFN-γ) - stimulated adherent monocytes were used to control for the anti-TLR-2 blocking of lipoprotein-induced IL-12. Adherent monocytes were treated with human IFN-γ (100 units/ml; Endogen, Cambridge, MA) for 16 hours to up-regulate CD40 expression. Cells were then treated with antibodies as stated above, then stimulated with soluble CD40L trimer (250 ng/ml; Immunex, Seattle, WA) for 16 hours. Neither antibody nor IFN-γ alone induced IL-12 production.
64. We thank P. Sieling, G. Cheng, M. Mark, C. Nathan, and H. Herschman for scientific discussion; M. Gately (Hoffman-La Roche) for POD-46D; and C. Nathan (Cornell Medical College, New York, NY) for the iNOS promoter. Supported by the NIH (to R.L.M., P.J.B., B.R.B., M.V.N.), the Howard Hughes Medical Institute (to B.R.B. and S.T.S.), the United Nations Development Programme/World Bank/World Health Organization Special Program for Research and Training in Tropical Diseases (IMMLEP), and the Dermatology Research Foundation of California, Incorporated.